Transcriptional adaptations during long-term persistence of Staphylococcus aureus in the airways of a cystic fibrosis patient

International Journal of Medical Microbiology

Volumn 305, Issue 1, 2015, Pages 38-46

  Windmüller, Nadine ^a   Witten, Anika ^b   Block, Desirée ^a   Bunk, Boyke ^c   Spröer, Cathrin ^c   Kahl, Barbara C ^a   Mellmann, Alexander ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Leibniz Institute for Arteriosclerosis Research   (Germany)

^c LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

Adaptation; Persistence; RNA sequencing; Staphylococcus aureus; Transcription

Indexed keywords

HOST FACTOR; VIRULENCE FACTOR;

ADAPTATION; AIRWAY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CASE REPORT; CYSTIC FIBROSIS; DOWN REGULATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENOME; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE EVASION; MALE; NONHUMAN; POINT MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 84940166532     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.10.005     Document Type: Article

References (69)

1. Agerberth B., Grunewald J., Castaños-Velez E., Olsson B., Jornvall H., Wigzell H., Eklund A., Gudmundsson G.H. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am. J. Respir. Crit. Care Med. 1999, 160:283-290.
2. Anderson M., Chen Y.H., Butler E.K., Missiakas D.M. EsaD, a secretion factor for the Ess pathway in Staphylococcus aureus. J. Bacteriol. 2011, 193:1583-1589.
3. Anderson M., Aly K.A., Chen Y.H., Missiakas D. Secretion of atypical protein substrates by the ESAT-6 Secretion System of Staphylococcus aureus. Mol. Microbiol. 2013, 90:734-743.
4. Atkins K.L., Burman J.D., Chamberlain E.S., Cooper J.E., Poutrel B., Bagby S., Jenkins A.T., Feil E.J., Elsen J.M., van den S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol. Immunol. 2008, 45:1600-1611.
5. Bakker E.P., Borchard A., Michels M., Altendorf K., Siebers A. High-affinity potassium uptake system in Bacillus acidocaldarius showing immunological cross-reactivity with the Kdp system from Escherichia coli. J. Bacteriol. 1987, 169:4342-4348.
6. Bals R., Hiemstra P.S. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur. Respir. J. 2004, 23:327-333.
7. Beaufort N., Wojciechowski P., Sommerhoff C.P., Szmyd G., Dubin G., Eick S., Kellermann J., Schmitt M., Potempa J., Magdolen V. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem. J. 2008, 410:157-165.
8. Berthet F.X., Rasmussen P.B., Rosenkrands I., Andersen P., Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998, 144(Pt 11):3195-3203.
9. Besier S., Smaczny C., Mallinckrodt C., von Krahl A., Ackermann H., Brade V., Wichelhaus T.A. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 2007, 45:168-172.
10. Bokarewa M.I., Jin T., Tarkowski A. Staphylococcus aureus: staphylokinase. Int. J. Biochem. Cell Biol. 2006, 38:504-509.
11. Braff M.H., Jones A.L., Skerrett S.J., Rubens C.E. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J. Infect. Dis. 2007, 195:1365-1372.
12. Branger C., Gardye C., Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J. Med. Microbiol. 1996, 45:294-301.
13. Burts M.L., Williams W.A., DeBord K., Missiakas D.M. EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus aureus infections. Proc. Natl. Acad. Sci. USA 2005, 102:1169-1174.
14. Burts M.L., DeDent A.C., Missiakas D.M. EsaC substrate for the ESAT-6 secretion pathway and its role in persistent infections of Staphylococcus aureus. Mol. Microbiol. 2008, 69:736-746.
15. Chaudhuri R.R., Loman N.J., Snyder L.A., Bailey C.M., Stekel D.J., Pallen M.J. xBASE2: a comprehensive resource for comparative bacterial genomics. Nucleic Acids Res. 2008, 36:D543-D546.
16. Chen Y.H., Anderson M., Hendrickx A.P., Missiakas D. Characterization of EssB, a protein required for secretion of ESAT-6 like proteins in Staphylococcus aureus. BMC Microbiol. 2012, 12. 219-2180-12-219.
17. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 2012, 18:509-519.
18. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2011, Cystic Fibrosis Foundation Patient Registry, Bethesda, MD, USA.
19. Derzelle S., Dilasser F., Duquenne M., Deperrois V. Differential temporal expression of the staphylococcal enterotoxins genes during cell growth. Food Microbiol. 2009, 26:896-904.
20. Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 2010, 363:2233-2247.
21. Förstner K.U., Vogel J., Sharma C.M. READemption - a tool for the computational analysis of deep-sequencing-based transcriptome data. Bioinformatics (Oxford, England) 2014, 10.1093/bioinformatics/btu533.
22. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3:948-958.
23. Gao W., Chua K., Davies J.K., Newton H.J., Seemann T., Harrison P.F., Holmes N.E., Rhee H.W., Hong J.I., Hartland E.L., Stinear T.P., Howden B.P. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog. 2010, 6:e1000944.
24. Garcia-Cuellar C., Cienfuegos L., Bautista R., Castillo-Rivera L., Alvarez-Jacobs J., Guerrero A.L., Garza, de la M. Kdp-like system in Salmonella typhimurium LT-2. Rev. Latinoam. Microbiol. 1995, 37:227-236.
25. Garofalo A., Giai C., Lattar S., Gardella N., Mollerach M., Kahl B.C., Becker K., Prince A.S., Sordelli D.O., Gomez M.I. The length of the Staphylococcus aureus protein A polymorphic region regulates inflammation: impact on acute and chronic infection. J. Infect. Dis. 2012, 206:81-90.
26. Goerke C., Papenberg S.M.y., Dasbach S., Dietz K., Ziebach R., Kahl B.C., Wolz C. Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J. Infect. Dis. 2004, 189:724-734.
27. Guinn K.M., Hickey M.J., Mathur S.K., Zakel K.L., Grotzke J.E., Lewinsohn D.M., Smith S., Sherman D.R. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol. Microbiol. 2004, 51:359-370.
28. Hirschhausen N., Block D., Bianconi I., Bragonzi A., Birtel J., Lee J.C., Dubbers A., Kuster P., Kahl J., Peters G., Kahl B.C. Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation. Int. J. Med. Microbiol. 2013, 303:685-692.
29. Hoboth C., Hoffmann R., Eichner A., Henke C., Schmoldt S., Imhof A., Heesemann J., Hogardt M. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 2009, 200:118-130.
30. Hogardt M., Hoboth C., Schmoldt S., Henke C., Bader L., Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 2007, 195:70-80.
31. Jin T., Bokarewa M., Foster T., Mitchell J., Higgins J., Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 2004, 172:1169-1176.
32. Kahl B., Herrmann M., Everding A.S., Koch H.G., Becker K., Harms E., Proctor R.A., Peters G. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 1998, 177:1023-1029.
33. Kahl B.C. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int. J. Med. Microbiol. 2010, 300:514-519.
34. Kahl B.C. Small colony variants (SCVs) of Staphylococcus aureus - a bacterial survival strategy. Infect. Genet. Evol. 2013, 10.1016/j.meegid.2013.05.016.
35. Kahl B.C., Belling G., Reichelt R., Herrmann M., Proctor R.A., Peters G. Thymidine-dependent small-colony variants of Staphylococcus aureus exhibit gross morphological and ultrastructural changes consistent with impaired cell separation. J. Clin. Microbiol. 2003, 41:410-413.
36. Kahl B.C., Duebbers A., Lubritz G., Haeberle J., Koch H.G., Ritzerfeld B., Reilly M., Harms E., Proctor R.A., Herrmann M., Peters G. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J. Clin. Microbiol. 2003, 41:4424-4427.
37. Kahl B.C., Goulian M., Wamel W., van Herrmann M., Simon S.M., Kaplan G., Peters G., Cheung A.L. Staphylococcus aureus RN6390 replicates and induces apoptosis in a pulmonary epithelial cell line. Infect. Immun. 2000, 68:5385-5392.
38. Kahl B.C., Mellmann A., Deiwick S., Peters G., Harmsen D. Variation of the polymorphic region X of the protein A gene during persistent airway infection of cystic fibrosis patients reflects two independent mechanisms of genetic change in Staphylococcus aureus. J. Clin. Microbiol. 2005, 43:502-505.
39. Konstan M.W., Wagener J.S., VanDevanter D.R. Characterizing aggressiveness and predicting future progression of CF lung disease. J. Cystic Fibrosis 2009, 8(Suppl. 1):S15-S19.
40. Laarman A.J., Ruyken M., Malone C.L., Strijp J.A., van Horswill A.R., Rooijakkers S.H. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J. Immunol. 2011, 186:6445-6453.
41. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (Oxford, England) 2009, 25:1754-1760.
42. McAdam P.R., Holmes A., Templeton K.E., Fitzgerald J.R. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. PLoS One 2011, 6:e24301.
43. Mwangi M.M., Wu S.W., Zhou Y., Sieradzki K., Lencastre H., Richardson de.P., Bruce D., Rubin E., Myers E., Siggia E.D., Tomasz A. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9451-9456.
44. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 2007, 120:13-22.
45. Nouwen J., Boelens H., Belkum A., van Verbrugh H. Human factor in Staphylococcus aureus nasal carriage. Infect. Immun. 2004, 72:6685-6688.
46. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
47. Pallen M.J. The ESAT-6/WXG100 superfamily - and a new Gram-positive secretion system?. Trends Microbiol. 2002, 10:209-212.
48. Parry M.A., Zhang X.C., Bode I. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem. Sci. 2000, 25:53-59.
49. Polarek J.W., Williams G., Epstein W. The products of the kdpDE operon are required for expression of the Kdp ATPase of Escherichia coli. J. Bacteriol. 1992, 174:2145-2151.
50. Pragman A.A., Yarwood J.M., Tripp T.J., Schlievert P.M. Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. J. Bacteriol. 2004, 186:2430-2438.
51. Proctor R.A., Eiff C., von Kahl B.C., Becker K., McNamara P., Herrmann M., Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 2006, 4:295-305.
52. Prokešová L., Porwit-Bóbr Z., Baran K., Potempa J., Pospíšil M., John C. Effect of metalloproteinase from Staphylococcus aureus on in vitro stimulation of human lymphocytes. Immunol. Lett. 1991, 27:225-230.
53. Rapaport F., Khanin R., Liang Y., Pirun M., Krek A., Zumbo P., Mason C.E., Socci N.D., Betel D. Comprehensive evaluation of differential gene expression analysis methods for RNA-Seq data. Genome Biol. 2013, 14:R95.
54. Renders N.H., van Belkum A., Overbeek S.E., Mouton J.W., Verbrugh H.A. Molecular epidemiology of Staphylococcus aureus strains colonizing the lungs of related and unrelated cystic fibrosis patients. Clin. Microbiol. Infect. 1997, 3:216-221.
55. Rooijakkers S.H., van Wamel W.J., Ruyken M., van Kessel K.P., van Strijp J.A. Anti-opsonic properties of staphylokinase. Microb. Infect. 2005, 7:476-484.
56. Schobert M., Tielen P. Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiol. 2010, 5:603-621.
57. Sharma C.M., Hoffmann S., Darfeuille F., Reignier J., Findeiß S., Sittka A., Chabas S., Reiche K., Hackermuller J., Reinhardt R., Stadler P.F., Vogel J. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 2010, 464:250-255.
58. Sieprawska-Lupa M., Mydel P., Krawczyk K., Wójcik K., Puklo M., Lupa B., Suder P., Silberring J., Reed M., Pohl J., Shafer W., McAleese F., Foster T., Travis J., Potempa J. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 2004, 48:4673-4679.
59. Sørensen A.L., Nagai S., Houen G., Andersen P., Andersen A.B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 1995, 63:1710-1717.
60. Sriramulu D.D., Lünsdorf H., Lam J.S., Römling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 2005, 54:667-676.
61. Stanley S.A., Raghavan S., Hwang W.W., Cox J.S. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13001-13006.
62. Stephens R.W., Vaheri A. Plasminogen 1993, Oxford University Press, NewYork, NY, USA.
63. Treuner-Lange A., Kuhn A., Dürre P. The kdp system of Clostridium acetobutylicum: cloning, sequencing, and transcriptional regulation in response to potassium concentration. J. Bacteriol. 1997, 179:4501-4512.
64. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., Wolfgang M.C., Boucher R., Gilpin D.F., McDowell A., Elborn J.S. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 177:995-1001.
65. Viviani L., Zolin A., van Rens J., Iansa P., Fox A., Preftitsi A., Pypops U., Mehta A., Ravilly S., Gulmans V., Oelsen H.V. Annual Data Report 2012, 2008-2009. ECFSPR.
66. Westermann A.J., Gorski S.A., Vogel J. Dual RNA-Seq of pathogen and host. Nat. Rev. Microbiol. 2012, 10:618-630.
67. Wolter D.J., Emerson J.C., McNamara S., Buccat A.M., Qin X., Cochrane E., Houston L.S., Rogers G.B., Marsh P., Prehar K., Pope C.E., Blackledge M., Deziel E., Bruce K.D., Ramsey B.W., Gibson R.L., Burns J.L., Hoffman L.R. Staphylococcus aureus small-colony variants are independently associated with worse Lung disease in children with cystic fibrosis. Clin. Infect. Dis. 2013, 57:384-391. 10.1093/cid/cit270.
68. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., Döring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002, 109:317-325.
69. + sensing and Agr signaling to infection programming. Infect. Immun. 2011, 79:2154-2167.